drugset / Trial / NCT03122197

Study of Letrozole in Recurrent Gliomas

NCT03122197

Phase 0 Recruiting 39 enrolled University of Cincinnati
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.

Timeline

Start
2017-05-16
Primary completion
2027-09-01
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Letrozole Other / unclassified 2.5 mg Oral
Subject Letrozole Other / unclassified 15 mg Oral
Subject Letrozole Other / unclassified 20 mg Oral
Background Temozolomide Small molecule 50 mg/m2 Oral

Indications